Literature DB >> 29471985

Heart failure with preserved ejection fraction: Classification based upon phenotype is essential for diagnosis and treatment.

Andrew Xanthopoulos1, Filippos Triposkiadis2, Randall C Starling3.   

Abstract

Heart failure (HF) is classified based upon the left ventricular ejection fraction (LVEF). Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous disorder with increasing prevalence in the elderly that remains incompletely understood and inadequately treated as no therapy has shown favorable effects. In this review, we summarize the current theories regarding HFpEF pathogenesis, propose a phenotype-based classification of HFpEF, discuss prevention strategies, explain why clinical trials on HFpEF treatment have failed, and make suggestions for the future.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Classification; Heart failure; Phenotypes; Preserved ejection fraction

Mesh：

Year:  2018        PMID： 29471985     DOI： 10.1016/j.tcm.2018.01.001

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN： 1050-1738            Impact factor:   6.677


  12 in total

1.  The midrange left ventricular ejection fraction (LVEF) is associated with higher all-cause mortality during the 1-year follow-up compared to preserved LVEF among real-world patients with acute heart failure: a single-center propensity score-matched analysis.

Authors:  Josip Anđelo Borovac; Katarina Novak; Josko Bozic; Duska Glavas
Journal:  Heart Vessels       Date:  2018-08-29       Impact factor: 2.037

Review 2.  Endothelial-cell-mediated mechanism of coronary microvascular dysfunction leading to heart failure with preserved ejection fraction.

Authors:  Yong Wang; Juan Zhang; Zhen Wang; Cheng Wang; Dufang Ma
Journal:  Heart Fail Rev       Date:  2022-03-09       Impact factor: 4.214

3.  An automatic approach for heart failure typing based on heart sounds and convolutional recurrent neural networks.

Authors:  Hui Wang; Xingming Guo; Yineng Zheng; Yang Yang
Journal:  Phys Eng Sci Med       Date:  2022-03-28

4.  Left Atrial Circulatory Assistance in Simulated Diastolic Heart Failure Model: First in Vitro and in Vivo.

Authors:  Chihiro Miyagi; Kiyotaka Fukamachi; Barry D Kuban; Shengqiang Gao; Takuma Miyamoto; Christine R Flick; Anthony R Polakowski; David J Horvath; Randall C Starling; Jamshid H Karimov
Journal:  J Card Fail       Date:  2022-01-10       Impact factor: 6.592

Review 5.  Obesity, inflammation, and heart failure: links and misconceptions.

Authors:  Filippos Triposkiadis; Andrew Xanthopoulos; Randall C Starling; Efstathios Iliodromitis
Journal:  Heart Fail Rev       Date:  2021-04-07       Impact factor: 4.214

Review 6.  Device-based treatment options for heart failure with preserved ejection fraction.

Authors:  Chihiro Miyagi; Takuma Miyamoto; Jamshid H Karimov; Randall C Starling; Kiyotaka Fukamachi
Journal:  Heart Fail Rev       Date:  2021-01-12       Impact factor: 4.214

Review 7.  Common Comorbidities that Alter Heart Failure Prognosis - Shaping New Thinking for Practice.

Authors:  Pupalan Iyngkaran; Merlin Thomas; John D Horowitz; Paul Komesaroff; Michael Jelinek; David L Hare
Journal:  Curr Cardiol Rev       Date:  2021

Review 8.  Management of heart failure with preserved ejection fraction.

Authors:  Emma Gard; Shane Nanayakkara; David Kaye; Harry Gibbs
Journal:  Aust Prescr       Date:  2020-02-03

9.  Identification of candidate biomarkers and therapeutic agents for heart failure by bioinformatics analysis.

Authors:  Vijayakrishna Kolur; Basavaraj Vastrad; Chanabasayya Vastrad; Shivakumar Kotturshetti; Anandkumar Tengli
Journal:  BMC Cardiovasc Disord       Date:  2021-07-04       Impact factor: 2.298

10.  Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis.

Authors:  Amera Halabi; Jonathan Sen; Quan Huynh; Thomas H Marwick
Journal:  Cardiovasc Diabetol       Date:  2020-08-05       Impact factor: 9.951
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.